Considering that ICIs therapy had been advocated as standard second-line therapy for NSCLC patients without EGFR/ALK genetic alteration56,57, the cohorts in our study should not have contained many patients with EGFR/ALK mutations. This evidence concerns the gene ALK and non-small cell lung carcinoma.